Improved Insulin Sensitivity With Angiotensin Receptor Neprilysin Inhibition in Individuals With Obesity and Hypertension

Clinical Pharmacology and Therapeutics

Volumn 101, Issue 2, 2017, Pages 254-263

  Jordan, J ^a   Stinkens, R ^b   Jax, T ^c   Engeli, S ^a   Blaak, E E ^b   May, M ^a   Havekes, B ^d   Schindler, C ^a   Albrecht, D ^e   Pal, P ^f   Heise, T ^c   Goossens, G H ^b   Langenickel, T H ^e  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c Profil   (Germany)

^d MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^e NOVARTIS PHARMA AG   (Switzerland)

^f Novartis Healthcare Pvt Ltd   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; GLYCEROL; PLACEBO; SACUBITRIL PLUS VALSARTAN; AMINOBUTYRIC ACID DERIVATIVE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; MEMBRANE METALLOENDOPEPTIDASE; NATRIURETIC FACTOR; TETRAZOLE DERIVATIVE;

ABDOMINAL SUBCUTANEOUS FAT; ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; BRAIN ARTERY ANEURYSM RUPTURE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; ENZYME INHIBITION; FEMALE; HEADACHE; HUMAN; HYPERINSULINEMIC-EUGLYCEMIC CLAMP TECHNIQUE; HYPERTENSION; INSULIN SENSITIVITY; LIPID METABOLISM; LIPID OXIDATION; LIPOLYSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; NEPHROLITHIASIS; OBESITY; ORTHOSTATIC HYPERTENSION; PERIPHERAL EDEMA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; TREATMENT DURATION; ADIPOSE TISSUE; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; ENERGY METABOLISM; GENETICS; INSULIN RESISTANCE; METABOLISM; PHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ADIPOSE TISSUE; ADULT; AMINOBUTYRATES; AMLODIPINE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; ENERGY METABOLISM; FEMALE; GLYCEROL; HUMANS; HYPERTENSION; INSULIN RESISTANCE; LIPID METABOLISM; MALE; MIDDLE AGED; NATRIURETIC PEPTIDES; NEPRILYSIN; OBESITY; RENIN-ANGIOTENSIN SYSTEM; TETRAZOLES;

EID: 85004064348     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.455     Document Type: Article

References (38)

1. Jordan, J. et al. Joint statement of the European Association for the Study of Obesity and the European Society of Hypertension: obesity and difficult to treat arterial hypertension. J. Hypertens. 30, 1047–1055 (2012).
2. Del Gobbo, L.C. et al. Contribution of major lifestyle risk factors for incident heart failure in older adults: the Cardiovascular Health Study. JACC Heart Fail. 3, 520–528 (2015).
3. Samuel, V.T., Petersen, K.F. & Shulman, G.I. Lipid-induced insulin resistance: unravelling the mechanism. Lancet 375, 2267–2277 (2010).
4. van Hees, A.M., Jans, A., Hul, G.B., Roche, H.M., Saris, W.H. & Blaak, E.E. Skeletal muscle fatty acid handling in insulin resistant men. Obesity (Silver Spring) 19, 1350–1359 (2011).
5. Schling, P. & Schäfer, T. Human adipose tissue cells keep tight control on the angiotensin II levels in their vicinity. J. Biol. Chem. 277, 48066–48075 (2002).
6. Standeven, K.F. et al. Neprilysin, obesity and the metabolic syndrome. Int. J. Obes. (Lond). 35, 1031–1040 (2011).
7. Wang, T.J. et al. Impact of obesity on plasma natriuretic peptide levels. Circulation 109, 594–600 (2004).
8. Magnusson, M. et al. Low plasma level of atrial natriuretic peptide predicts development of diabetes: the prospective Malmo Diet and Cancer study. J. Clin. Endocrinol. Metab. 97, 638–645 (2012).
9. Meirhaeghe, A. et al. Association between the T-381C polymorphism of the brain natriuretic peptide gene and risk of type 2 diabetes in human populations. Hum. Mol. Genet. 16, 1343–1350 (2007).
10. Jujić, A., Nilsson, P.M., Engström, G., Hedblad, B., Melander, O. & Magnusson, M. Atrial natriuretic peptide and type 2 diabetes development–biomarker and genotype association study. PLoS One 9, e89201 (2014).
11. Birkenfeld, A.L. et al. Lipid mobilization with physiological atrial natriuretic peptide concentrations in humans. J. Clin. Endocrinol. Metab. 90, 3622–3628 (2005).
12. Birkenfeld, A.L. et al. Atrial natriuretic peptide induces postprandial lipid oxidation in humans. Diabetes 57, 3199–3204 (2008).
13. Coué, M. et al. Defective natriuretic peptide receptor signaling in skeletal muscle links obesity to type 2 diabetes. Diabetes 64, 4033–4045 (2015).
14. Engeli, S. et al. Natriuretic peptides enhance the oxidative capacity of human skeletal muscle. J. Clin. Invest. 122, 4675–4679 (2012).
15. van der Zijl, N.J., Moors, C.C., Goossens, G.H., Hermans, M.M., Blaak, E.E. & Diamant, M. Valsartan improves {beta}-cell function and insulin sensitivity in subjects with impaired glucose metabolism: a randomized controlled trial. Diabetes Care 34, 845–851 (2011).
16. McMurray, J.J. et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N. Engl. J. Med. 371, 993–1004 (2014).
17. Langenickel, T.H. & Dole, W.P. Angiotensin receptor-neprilysin inhibition with LCZ696: a novel approach for the treatment of heart failure. Drug Discov. Today Ther. Strateg. 9, e131–e139 (2012).
18. Hall, J.E., do Carmo, J.M., da Silva, A.A., Wang, Z. & Hall, M.E. Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. Circ. Res. 116, 991–1006 (2015).
19. Morris, M.J. Cardiovascular and metabolic effects of obesity. Clin. Exp. Pharmacol. Physiol. 35, 416–419 (2008).
20. Jing, F., Mogi, M. & Horiuchi, M. Role of renin-angiotensin-aldosterone system in adipose tissue dysfunction. Mol. Cell. Endocrinol. 378, 23–28 (2013).
21. Navigator Study Group et al. Effect of valsartan on the incidence of diabetes and cardiovascular events. N. Engl. J. Med. 362, 1477–1490 (2010).
22. Goossens, G.H. The renin-angiotensin system in the pathophysiology of type 2 diabetes. Obes. Facts 5, 611–624 (2012).
23. Wang, T.J., Larson, M.G., Keyes, M.J., Levy, D, Benjamin, E.J. & Vasan, R.S. Association of plasma natriuretic peptide levels with metabolic risk factors in ambulatory individuals. Circulation 115, 1345–1353 (2007).
24. Boschmann, M. et al. Influences of AT1 receptor blockade on tissue metabolism in obese men. Am. J. Physiol. Regul. Integr. Comp. Physiol. 290, R219–R223 (2006).
25. Eriksson, A.K. et al. Endothelin-1 stimulates human adipocyte lipolysis through the ET A receptor. Int. J. Obes. (Lond). 33, 67–74 (2009).
26. Mori, M.A. et al. Kinin B1 receptor in adipocytes regulates glucose tolerance and predisposition to obesity. PLoS One 7, e44782 (2012).
27. Fryer, R.M. et al. Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema. Br. J. Pharmacol. 153, 947–955 (2008).
28. Kobalava, Z. et al. Pharmacodynamic and pharmacokinetic profiles of sacubitril/valsartan (LCZ696) in patients with heart failure and reduced ejection fraction. Cardiovasc. Ther. 34, 191–198 (2016).
29. Gu, J. et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J. Clin. Pharmacol. 50, 401–414 (2010).
30. Birkenfeld, A.L., Adams, F., Schroeder, C., Engeli, S. & Jordan, J. Metabolic actions could confound advantageous effects of combined angiotensin II receptor and neprilysin inhibition. Hypertension 57, e4–e5 (2011).
31. Miyashita, K. et al. Natriuretic peptides/cGMP/cGMP-dependent protein kinase cascades promote muscle mitochondrial biogenesis and prevent obesity. Diabetes 58, 2880–2892 (2009).
32. Sengenès, C. et al. Natriuretic peptide-dependent lipolysis in fat cells is a primate specificity. Am. J. Physiol. Regul. Integr. Comp. Physiol. 283, R257–R265 (2002).
33. Ramirez, C.E. et al. Treatment with sildenafil improves insulin sensitivity in prediabetes: a randomized, controlled trial. J. Clin. Endocrinol. Metab. 100, 4533–4540 (2015).
34. Kario, K. et al. Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study. Hypertension 63, 698–705 (2014).
35. Drexler, H., Riede, U., Münzel, T., König, H., Funke, E. & Just, H. Alterations of skeletal muscle in chronic heart failure. Circulation 85, 1751–1759 (1992).
36. Kemppainen, J. et al. Insulin signalling and resistance in patients with chronic heart failure. J. Physiol. 550(Pt1), 305–315 (2003).
37. Doehner, W. et al. Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure. J. Am. Coll. Cardiol. 46, 1019–1026 (2005).
38. Goossens, G.H., Blaak, E.E., Saris, W.H. & van Baak, M.A. Angiotensin II-induced effects on adipose and skeletal muscle tissue blood flow and lipolysis in normal-weight and obese subjects. J. Clin. Endocrinol. Metab. 89, 2690–2696 (2004).